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ANTIISCHEMIC AND A~TIA~~I AL EFFECTNEMESS OF AMLODIFINE, A 
ANTAGONIST, IN THE TREAT 
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q-acting dihydropyridine calcium 
was evaluated for antibchemic and antianginal effcacy 
antagonist, 
in 12 patients (pts) 
with dot. CAD, stable angina pectoris (AP) and > 4 mm of exercise - induced 
ST - segment depression (ST&). For 2 days pts received A at 8 a.m.. 
According to a randomized, placebo - cant , crossover and db protocol, 
pts were then assigned to A or placebo (P) taken once a day at 8 a.m. 
for 3 weeks each with 2 intercurrent weeks nshout. During both 
treatment phases, diaries were kept for angina1 attacks. Exercise tests and 
blood sampling for plasma levels ~0 A were performed before (= 24h) and 8 
hours after dosing on the following day after acute testing as well as on day 18 
of each of the 3 weeks. Effects (percent changes) on STL at comparable 
workload, exercise capacity (EC, in W x min) w%nout AP (EC - AP), EC with- 
out ischemia (EC - STJ.) during acute and chronic treatment, AP - attacks du- 
ring chronic treatment and corresponding plasma levels (PL, in ng ml) were 
(chro~lc) 24 
-30%‘“’ -3l%- 
4-I 0% -I-. 5% 
+?4%- +I 08%“” 
23.90 12.07 
45%” 
.05;~B,<.Q1;-g,c.o05as~ red to controk P 
is an effective antiischemic and antianginal agent. It warrants 
therapeutic coverage for at feast 24 hours ith the advantage of dosing 
once daily. During chronic treatment, antiischemic effects increased at 24 
hours which was considered due to higher plasma levels after repeated 
administration. 
